newsfilter
← Latest News
Business Wire·

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

More than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery Data demonstrated statistically significant and clinically